Infectious Disease Clinical Trials

Statistical methods in infectious disease trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All infectious disease trials

903 results

• Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients: Complete Statistical AnalysisIndependent statistical analysis of Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 2NCT04748120
• Optimal Care of Complicated Appendicitis: Complete Statistical AnalysisIndependent statistical analysis of Optimal Care of Complicated Appendicitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03159754).Phase 4Results postedn = 40NCT03159754
• Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe: Complete Statistical AnalysisIndependent statistical analysis of Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 18NCT01465048
• Optimization of a New Adaptive Intervention to Increase COVID-19 Testing: Complete Statistical AnalysisIndependent statistical analysis of Optimization of a New Adaptive Intervention to Increase COVID-19 Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04757298).Phase NAResults postedn = 668NCT04757298
• Optimizing HPV Vaccine Introduction in Shanghai, China: Complete Statistical AnalysisIndependent statistical analysis of Optimizing HPV Vaccine Introduction in Shanghai, China: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03972813).Phase NAResults postedn = 1,021NCT03972813
• Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya: Complete Statistical AnalysisIndependent statistical analysis of Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00428116).Phase NAResults postedn = 140NCT00428116
• OPTISCREEN-BIndependent statistical analysis of Application of HBV Rapid Tests as a Tool for Wide-Use Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 1,000NCT01767597
• Oral Health Literacy Tailored Communication: Complete Statistical AnalysisIndependent statistical analysis of Oral Health Literacy Tailored Communication: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01118143).Phase NAResults postedn = 179NCT01118143
• Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women: Complete Statistical AnalysisIndependent statistical analysis of Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 1,671NCT03354598
• ORBIT-4An independent statistical analysis of the randomized phase 3 ORBIT-4 trial evaluating ciprofloxacin dispersion for inhalation versus placebo in non-CF bronchiectasis, including trial design, endpoint definition, planned time-to-event analysis, and statistical interpretation.Phase 3n = 304NCT02104245
• OsteosarcomaIndependent statistical analysis of Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01336803).Phase 2Results postedn = 32NCT01336803
• OZGAMIndependent statistical analysis of Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02431650).Phase 1/2Results postedn = 11NCT02431650
• PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 69NCT00567840
• PACSIndependent statistical analysis of Cranberry for UTI Prevention in Residents of Long Term Care Facilities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 56NCT00596635
• PADD-ONIndependent statistical analysis of Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 170NCT01524679
• Pain Control Following Sinus Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pain Control Following Sinus Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03783702).Phase 4Results postedn = 118NCT03783702
• Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: Complete Statistical AnalysisIndependent statistical analysis of Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 100NCT01006629
• Palu-COVIDIndependent statistical analysis of Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 238NCT05012280
• PAPALIndependent statistical analysis of A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01667107).Phase 4Results postedn = 26NCT01667107
• PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD): Complete Statistical AnalysisIndependent statistical analysis of PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 535NCT00468728
• Parrying the Pitfalls of PrEP: Project PEACH: Complete Statistical AnalysisIndependent statistical analysis of Parrying the Pitfalls of PrEP: Project PEACH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05072093).Phase 4Results postedn = 240NCT05072093
• Partners Demonstration ProjectAn independent statistical analysis of the Partners Demonstration Project (NCT02775929), evaluating PrEP and ART implementation strategies for HIV-1 serodiscordant couples, including trial design, endpoints, planned analyses, and statistical interpretation.Phase 4n = 1,013NCT02775929
• PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 1,821NCT04613375
• PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection: Complete Statistical AnalysisIndependent statistical analysis of PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03239899).Phase 1Results postedn = 13NCT03239899
• PEARL-IIndependent statistical analysis of A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection: primary endpoint results,…Phase 2Results postedn = 316NCT01685203
• PEARL-IVIndependent statistical analysis of A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 305NCT01833533
• Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto): Complete Statistical AnalysisIndependent statistical analysis of Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02918773).Phase NAResults postedn = 22NCT02918773
• Pediatric Head Lice Study Product Comparison: Complete Statistical AnalysisIndependent statistical analysis of Pediatric Head Lice Study Product Comparison: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02213055).Phase 2Results postedn = 97NCT02213055
• Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: Complete Statistical AnalysisIndependent statistical analysis of Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00944073).Phase 2Results postedn = 583NCT00944073
• PeerPrEPIndependent statistical analysis of Peer PrEP Referral + HIV Self-test Delivery for PrEP Initiation in Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 211NCT04982250
• Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 160NCT00202839
• PEGHOPEIndependent statistical analysis of An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy: primary…Phase NAResults postedn = 88NCT01416610
• Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 377NCT00491244
• Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02940496).Phase 2Results postedn = 15NCT02940496
• Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 12NCT02767934
• Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02267603).Phase 2Results postedn = 50NCT02267603
• PEOPLEComplete statistical analysis of the PEOPLE phase 3 trial of post-exposure prophylaxis for leprosy in the Comoros and Madagascar, including trial design, incidence rate ratios, mixed-effects methodology, confidence intervals, and interpretation.Phase 3Results postedn = 144,000NCT03662022
• PEOPLEIndependent statistical analysis of Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03662022).Phase 3Results postedn = 144,000NCT03662022
• PEPSIndependent statistical analysis of Prevention of Peritonitis in Peritoneal Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01293799).Phase NAResults postedn = 713NCT01293799
• Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 582NCT00891176
• Persistence of Protection by Shingrix: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Protection by Shingrix: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04169009).Phase 4Results postedn = 105NCT04169009
• Pertussis Infection in Adolescents and Adults With Prolonged Cough: Complete Statistical AnalysisIndependent statistical analysis of Pertussis Infection in Adolescents and Adults With Prolonged Cough: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01597687).Phase NAResults postedn = 337NCT01597687
• PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects: Complete Statistical AnalysisIndependent statistical analysis of PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 46NCT03581305
• PFAS Exposure and Immune Response to Vaccination in Adults: Complete Statistical AnalysisIndependent statistical analysis of PFAS Exposure and Immune Response to Vaccination in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06588530).Phase 4Results postedn = 20NCT06588530
• Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 12NCT01524302
• Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED): primary endpoint results, effect estimate…Phase NAResults postedn = 901NCT00723632
• Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 26NCT01660321
• Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 15NCT04371380
• Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function: primary endpoint results, effect…Phase 1Results postedn = 25NCT03562117
• Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 30NCT05630872

← All therapeutic areas